Anixa Biosciences, Inc. (NasdaqCM: ANIX)
Health Care · Biotechnology · US
$3.66
-1.35% today · +21.2% 1Y
Anixa Biosciences, Inc. (NasdaqCM: ANIX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $126.23M and employs 4 people.
Over the last twelve months the share price has gained 21.2%, trading between 2.32 and 5.46.
Tweenvest scores Anixa Biosciences, Inc. across four factors: quality 27/100. Its strongest factor is quality.
ANIX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $126.23M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.30
- Dividend yield
- —
- Beta (5Y)
- 0.52
- 52-week high
- $5.46
- 52-week low
- $2.32
- Avg volume (3M)
- —
- Shares outstanding
- 34.02M
- Employees
- 4
- Next earnings
- —
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
- ISIN
- US03528H1095
- Founded
- 1982
- Listed since
- Oct 7, 1983
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.49 | -0.84% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.